BioSpace News Archive

TriSalus Life Sciences®, an immunotherapy company on a mission to extend and improve the lives of patients living with liver and pancreatic tumors, today announced a strategic research collaboration with the University of Colorado Anschutz Medical Campus to advance research of immuno-oncology treatments for patients with liver and pancreatic tumors.

China SXT Pharmaceuticals, Inc. announced the closing of an underwritten public offering of its ordinary shares and prefunded warrants to purchase ordinary shares, and the simultaneous closing of the overallotment option, with gross proceeds to the Company to be approximately $4.1 million, assuming the pre-funded warrants will be fully exercised and before deducting underwriting discounts and commissions and other estimated expenses payable by the Company.

Once the clinical data has been completed and tabulated, the final results will be reported to the marketplace and the U.S. Food & Drug Administration for Emergence Use Authorization consideration.

According to a study published by the WHO, heart disease is one of the major causes of death in the world, with nearly 17.9 million of the population dying of the disease each year.

Rapid growth of biopharmaceutical sector, growing demand for personalized medicine, and increasing research activities using humanized mice models are key factors driving revenue market growth.

The San Francisco Bay Area is the world leader in Life Science. Vacaville has been successful at attracting top biotech companies, including Genentech and just recently the Boston-based Agenus.

Probo Medical (“Probo”), a leading global provider of medical imaging equipment, parts, repair and service, today announced the completion of its acquisition of REMETRONIX. Terms of the transaction were not disclosed.

Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today announced that the Company’s leadership will participate in two upcoming conferences in January and February 2022.

Opiant Pharmaceuticals, Inc. announced the Compensation Committee of the Company’s Board of Directors has approved the grant of restricted stock units covering an aggregate of 31,500 shares of common stock to six hired employees, pursuant to the Company’s 2021 Inducement Equity Incentive Plan.

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the initiation of the Phase 2a PREVAIL-2 study (PRV-3279 EVAluation In Lupus- Phase 2).